A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera
Future Oncology · 2023
DOI: 10.2217/fon-2022-1141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Jie Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Polycythemia Vera, Interferon alpha-2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PharmaEssentia Corporation.
Abstract (Originalsprache)
Ropeginterferon α-2b is a mono-PEGylated proline-interferon for the treatment of polycythemia vera. This drug is used biweekly with a starting dose of 100 μg (50 μg if patients receiving hydroxyurea) and 50 μg increments up to a maximum dose of 500 μg. Increasing evidence indicates that patients can tolerate higher starting doses of ropeginterferon α-2b. This phase II trial utilizes 250 μg as the starting dose, 350 μg at week 2 and 500 μg at week 4 as the target dose. Doses can be adjusted according to tolerability. This study assesses the safety, efficacy and molecular response of ropeginterferon α-2b in Chinese patients with PV utilizing the 250-350-500 μg dosing schema. This study will be used to support the application of a biologics license for polycythemia vera treatment in China. Polycythemia vera (PV) is a slow-growing blood neoplasm (cells that grow and divide more than they should or do not die when they should). PV often has a mutation in the gene called JAK2, which causes changes in the DNA of genes that cause cells to become cancerous. PV is associated with an increased number of blood cells, debilitating symptoms, risks of thrombosis (blood clot) and bleeding and can progress to other diseases, including myelofibrosis and acute myeloid leukemia. Ropeginterferon α-2b is a new product with favorable properties, allowing a convenient dosing schedule of every 2–4 weeks. This drug has demonstrated good tolerability, safety and efficacy for PV treatment and has been approved for the treatment of PV in Europe and the USA. This article discusses the design of an ongoing study that looks at the safety and efficacy of ropeginterferon α-2b for the treatment of PV. The study follows a specific dosing schedule, with the aim of controlling the neoplasm faster, and plans to include 49 patients from 12–15 major hospitals in China. Clinical Trial Registration: This trial is registered at ClinicalTrials.gov (identifier: NCT05485948) and in China (China National Medical Products Administration Clinical Trial Registration Number: CTR20211664).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- PharmaEssentia Corporation, Taipei, Taiwan.
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China.
- PharmaEssentia Biotech (Beijing) Ltd, Beijing, China.
ORCID-Profile: Jie Jin, Albert Qin
Förderung
- PharmaEssentia Corporation
Zitieren
APA
Jin, J., Qin, A., Zhang, L., Shen, W., Wang, W., Zhang, J., Li, Y., Wu, D., & Xiao, Z. (2023). A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera. Future Oncology. https://doi.org/10.2217/fon-2022-1141
Vancouver
Jin J, Qin A, Zhang L, Shen W, Wang W, Zhang J, et al. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera. Future Oncology. 2023. doi:10.2217/fon-2022-1141
BibTeX
@article{Jin2023,
author = {Jin, Jie and Qin, Albert and Zhang, Lei and Shen, Weihong and Wang, Wei and Zhang, Jingjing and Li, Yaning and Wu, Daoxiang and Xiao, Zhijian},
title = {A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2022-1141}
}
EUVIMED